114 - Clinical Controversies in the Treatment of S. aureus Bacteremia

Friday, October 21, 2022

10:30 AM – 11:45 AM US ET

Location: 202 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Thomas Holland, MD

Associate Professor, Department of Medicine, Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina, United States

Disclosure(s): Aridis: Advisor/Consultant (); Basilea Pharmaceutica: Advisor/Consultant (); Karius: Advisor/Consultant (); Lysovant: Advisor/Consultant ()
Timothy Jenkins, MD

Associate Professor
Infectious Diseases, Medicine
Denver Health and Hospital Authority
Denver, Colorado, United States

Disclosure(s): Basilea: Clinical outcomes adjudication committee ()

Faculty(s)

E.R. Chulie Ulloa, MD, MSc

Assistant Professor
University of California, Irvine, School of Medicine

Disclosure(s): No financial relationships to disclose

Slides
Warren Rose, PharmD, MPH

Associate Professor
Pharmacy
University of Wisconsin-Madison
Madison, WI, United States

Disclosure(s): Merck and Company, Inc.: Grant/Research Support (Ongoing); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing)

Slides
Brian Werth, PharmD

Associate Professor of Pharmacy
Department of Pharmacy
University of Washington School of Pharmacy
Seattle, WA, United States

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Thomas L. Holland, MD: Aridis: Advisor/Consultant (); Basilea Pharmaceutica: Advisor/Consultant (); Karius: Advisor/Consultant (); Lysovant: Advisor/Consultant ()

Timothy C. Jenkins, MD: Basilea: Clinical outcomes adjudication committee ()

E.R. Chulie Ulloa, MD, MSc: No financial relationships to disclose

Warren Rose, PharmD, MPH: Merck and Company, Inc.: Grant/Research Support (Ongoing); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing)

Brian J. Werth, PharmD: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

apply strategies for the management of persistent S. aureus bacteremia;
critically appraise the evidence behind nonstandard treatment options for S. aureus bacteremia;
understand the role of combination antibiotic therapy for MRSA bacteremia

Presentations:

10:30 AM – 10:55 AM US ET

Management of Persistent MSSA Bacteremia
Speaker: E.R. Chulie Ulloa, MD, MSc – University of California, Irvine, School of Medicine
10:55 AM – 11:20 AM US ET

Should Daptomycin + Ceftaroline Be Standard of Care for MRSA Bacteremia?
Speaker: Warren Rose, PharmD, MPH – University of Wisconsin-Madison
11:20 AM – 11:45 AM US ET

Use of Nonstandard Therapies for SAB - Lipoglycopeptides, Oral Antibiotics and More
Speaker: Brian J. Werth, PharmD – University of Washington School of Pharmacy